Table 1.
Baseline characteristics of the intent-to-treat population
| Favipiravir (N=112) | SOC (N=56) | |
|---|---|---|
| Age, years | ||
| Mean (SD) | 41.7 (10.6) | 42.0 (10.4) |
| Sex | ||
| Female | 63 (56.2%) | 26 (46.4%) |
| Male | 49 (43.8%) | 30 (53.6%) |
| Race* | ||
| Caucasian | 111 (99.1%) | 55 (98.2%) |
| Asian | 1 (0.9%) | 1 (1.8%) |
| Patient cohort | ||
| Outpatients-no. (%) | 83 (74.1%) | 44 (78.6%) |
| Hospitalized patients-no. (%) | 29 (25.9%) | 12 (21.4%) |
| Time from the first symptom onset to randomization | ||
| Mean (SD), days | 3.5 (1.4) | 3.6 (1.4) |
| ≤3 days | 53 (47.3%) | 24 (42.9%) |
| 4-6 days | 59 (52.7%) | 32 (57.1%) |
| Disease severity at baseline | ||
| Mild | 28 (25.0%) | 15 (26.8%) |
| Moderate | 84 (75.0%) | 41 (73.2%) |
| Score on Ordinal scale at baseline | ||
| 1-ambulatory. no limitation of activities | 14 (12.5%) | 13 (23.2%) |
| 2-ambulatory. limitation of activities | 69 (61.6%) | 31 (55.4%) |
| 3-hospitalized. no oxygen therapy | 28 (25.0%) | 10 (17.9%) |
| 4-hospitalized. oxygen by mask or nasal prongs | 1 (0.9%) | 2 (3.6%) |
| Severity according to CT | ||
| CT-0 | 28 (25.0%) | 13 (23.2%) |
| CT-1 | 66 (58.9%) | 33 (58.9%) |
| CT-2 | 12 (10.7%) | 8 (14.3%) |
| CT-3 | 6 (5.4%) | 1 (1.8%) |
| Hyperthermia at baseline | 79 (70.5%) | 43 (76.8%) |
Data are n (%) unless otherwise stated.
*
Race was reported by the patients.